Handbrake off in growth drive Aberdeen Standard European Logistics Income’s (ASLI’s) manager has taken a prudent approach to growing the fund thus far, taking a little-and-often capital raise strategy to improve the quality of the portfolio. However, it now proposes a £75m placing to help fund an identified investment pipeline worth €165m and take advantage […]
Essa Pharmaceutials (Nasdaq: EPIX) and Moderna (MRNA) may have been the top performers within Swiss investment company BB Biotech’s (SIX:BION) 34-strong portfolio in the first half, sporting stock price rises of 137% and 124% respectively, but these gains are modest by comparison with some of the ones from within the wider world of biotech investing. […]
QD view – on drugs… and other aspects of healthcare. Rate worries hitting growth stocks After delivering impressive returns last year, the tech and biotech sectors have stumbled a bit recently. It seems unfair that trusts such as Polar Capital Technology and Allianz Technology are now trading on discounts. However, some investors are worried about […]
BB Biotech’s bet on a positive US regulatory review of Biogen’s controversial Alzheimer’s disease therapy aducanumab is poised for its denouement, with the PDUFA date – the deadline for the FDA to render an approval decision – now less than two weeks away. The Swiss investment firm acquired a stake in Biogen (accounting for 3.3% […]
Economic and Political Monthly Roundup Kindly sponsored by Allianz A collation of recent insights on markets and economies taken from the comments made by chairmen and investment managers of investment companies – have a read and make your own minds up. Please remember that nothing in this note is designed to encourage you to buy or […]
In QuotedData’s morning briefing 26 April 2021 – International Biotechnology Trust’s (IBT’s) interim results to 28 February 2021 saw the NAV per share return 6.9%. On the management side, Carl Harald Janson decided to step back from his role as lead manager (he will remain involved with IBT as a senior advisor) and Kate Bingham was welcomed back […]
Investment Companies Quarterly Roundup Kindly sponsored by Baillie Gifford and Aberdeen Standard Investments £2.9bn of net new capital raised It felt as though the rotation from ‘growth’ to ‘value’ that began last November picked up momentum towards the end of the first quarter. UK equity and property assets had a strong start to the year. Some […]
Investment Companies Monthly Roundup Kindly sponsored by Baillie Gifford and Aberdeen Standard Investments Research published over March Aberdeen Emerging Markets Investment Company – Cautiously optimistic “Aberdeen Emerging Markets Investment Company’s (AEMC’s) managers, Andrew Lister and Bernard Moody, note investors’ new-found enthusiasm for emerging markets, now that they have been outperforming for a while. Their long experience […]
In QuotedData’s morning briefing 15 March 2021 – International Biotechnology Trust’s (IBT’s) board and its manager, SV Health Investors, announced that Carl Harald Janson has decided to step back from his role as lead manager after seven at the helm. Lead responsibility for portfolio management will transition to Ailsa Craig and Marek Poszepczynski and the board […]
A leading biotech investor BB Biotech is the oldest-established, the largest and, over the longer term, one of the best-performing of the small group of closed-end funds that specialise in the biotech sector. It offers investors a vehicle to gain exposure to a focused portfolio of predominantly-US small-to-mid-cap biotech companies developing therapeutic products, with a […]
